North Carolina is currently home to 2644 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Durham, Charlotte, Winston-Salem and Chapel Hill. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
Written Exposure Therapy to Improve Recovery Among Sexual Assault Survivors
NCT06571513
Recruiting
The main objective of this pilot trial is to determine the feasibility and initial efficacy of telehealth-delivered written exposure therapy to reduce the development of posttraumatic stress disorder after sexual assault. This pilot trial will provide the data necessary to design and support a large-scale trial.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/07/2024
Locations: University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
Conditions: Post-traumatic Stress Disorder
Register for Updates
Behavioral Approaches to Reduce Diabetes Distress in Adults With Type 1 Diabetes: A Pragmatic SMART
NCT06405373
Recruiting
This study is designed to compare two behavioral approaches to reduce diabetes distress ("the expected burdens, concerns, fears, and threats that arise from the challenges of living with diabetes") in adults with type 1 diabetes. At the study baseline, participants will be randomized to take part in one of two virtual, group-based interventions (the "Primary" intervention) utilizing either an emotions-focused or a problem-solving approach to reduce diabetes distress. After the initial interventi... Read More
Gender:
ALL
Ages:
30 years and above
Trial Updated:
10/07/2024
Locations: University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
Conditions: Diabetes type1, Diabetes Mellitus, Type 1, Diabetes, Autoimmune, Diabetes Mellitus, Distress, Emotional
Register for Updates
CIED Infection Quality Initiative Demonstration Project
NCT05471973
Recruiting
The aim of this Quality Initiative (QI) demonstration project is to develop a model to increase guideline-driven care for patients with cardiovascular implantable electronic devices (CIED) infection. Multidisciplinary teams will be established to carry out the multifaceted intervention. This program seeks to improve early identification and diagnosis, appropriate treatment, and faster time to treatment of CIED infection.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/07/2024
Locations: Atrium Health, Charlotte, North Carolina
Conditions: Infections
Register for Updates
Targeted Lifestyle Change Group Prenatal Care
NCT04090307
Recruiting
To conduct a randomized trial to determine the effect of Targeted Lifestyle Change Group Prenatal Care (TLC) on maternal and neonatal outcomes in women at high risk for developing gestational diabetes mellitus (GDM).
Gender:
FEMALE
Ages:
13 years and above
Trial Updated:
10/07/2024
Locations: University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
Conditions: Pregnancy, Gestational Diabetes
Register for Updates
Post Approval Study for Treatment of Drug-resistant Adult and Pediatric Primary FSGS Using the LIPOSORBER® LA-15 System
NCT04065438
Recruiting
This multicenter, prospective, single-arm clinical study will evaluate the probable benefit and safety of the LIPOSORBER® LA-15 System for the treatment of adult patients with nephrotic syndrome associated with primary focal segmental glomerulosclerosis, when the standard treatment options, including corticosteroid and/or calcineurin inhibitors treatments, have been unsuccessful or not well tolerated, and the patient has a GFR ≥ 45 ml/min/1.73m2, or the patient has post-renal transplant recurren... Read More
Gender:
ALL
Ages:
75 years and below
Trial Updated:
10/07/2024
Locations: University of North Carolina, Chapel Hill, North Carolina
Conditions: Focal Segmental Glomerulosclerosis
Register for Updates
Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone
NCT03295981
Recruiting
The purpose of the clinical study is to investigate whether the local delivery of bisphosphonate as a surgical adjuvant can decrease the chance of a giant cell tumor of bone coming back to the same location. The hypothesis is that the local administration of bisphosphonate will decrease the rate of the tumor returning compared to traditional aggressive surgical removal of the tumor.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/07/2024
Locations: Wake Forest University, Winston-Salem, North Carolina
Conditions: Giant Cell Tumor of Bone
Register for Updates
Chlorhexidine Gluconate Bathing Education Video Among Hospitalized Patients
NCT06112626
Recruiting
Chlorhexidine gluconate (CHG) bathing is an effective intervention to reduce hospitalized patient's risk of acquiring a central line-associated bloodstream infection (CLABSI). While daily CHG bathing for hospitalized patients is widely supported in the literature, patient adherence with this practice is suboptimal. Written and verbal information is provided to patients by nursing staff regarding the importance of CHG bathing and the correct usage of the CHG cloths; however, these methods can be... Read More
Gender:
ALL
Ages:
All
Trial Updated:
10/03/2024
Locations: Duke University Hospital, Durham, North Carolina
Conditions: Infections
Register for Updates
A Study of AAV2-hAQP1 Gene Therapy in Participants With Radiation-Induced Late Xerostomia
NCT05926765
Recruiting
This study will assess the efficacy and safety of bilateral intra-parotid administration of AAV2-hAQP1 in adults with Grade 2 or Grade 3 radiation-induced late xerostomia.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/03/2024
Locations: UNC-Chapel Hill, Chapel Hill, North Carolina
Conditions: Grade 2 and 3 Late Xerostomia Caused by Radiotherapy for Cancers of the Upper Aerodigestive Tract, Excluding the Parotid Glands
Register for Updates
C-TIL051 in Non-Small Cell Lung Cancer
NCT05676749
Recruiting
The goal of this Phase 1 clinical study is test tumor infiltrating lymphocytes (known as C-TIL051) with NKTR-255 and anti-PD1 therapy for subjects with refractory non-small cell lung cancer. The purpose of this study is to: 1. Test the safety and ability for subjects to tolerate the TIL therapy 2. Measure to see how the NSCLC responds to the TIL therapy Participants will be asked to: * Provide a tumor sample prior to the start of any treatment which will be used to make the C-TIL051. * Recei... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/03/2024
Locations: Duke Center for Cancer Immunotherapy, Raleigh, North Carolina
Conditions: Metastatic Non Small Cell Lung Cancer
Register for Updates
Aimovig Pregnancy Exposure Registry
NCT06150781
Recruiting
The primary objective of this study is to estimate the proportion of major congenital malformations in infants of women with migraine exposed to erenumab-aooe during pregnancy compared to infants of women with migraine unexposed to erenumeb-aooe.
Gender:
FEMALE
Ages:
Between 18 years and 99 years
Trial Updated:
10/02/2024
Locations: IQVIA Virtual Site, Durham, North Carolina
Conditions: Migraine
Register for Updates
A Phase 1, Dose Escalation Trial of RP-A601 in Subjects With PKP2 Variant-Mediated Arrhythmogenic Cardiomyopathy (PKP2-ACM)
NCT05885412
Recruiting
This Phase 1 dose escalation trial will assess the safety and preliminary efficacy of a single dose intravenous infusion of RP-A601 in high-risk adult patients with PKP2-ACM.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/02/2024
Locations: Duke University, Durham, North Carolina
Conditions: PKP2 Arrhythmogenic Cardiomyopathy (PKP2-ACM)
Register for Updates
A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors
NCT05150691
Recruiting
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/02/2024
Locations: Regional Medical Oncology Center, Wilson, North Carolina
Conditions: HER2-positive Advanced Solid Tumor
Register for Updates